Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacillus subtilis CU1
- Development stage
- Unknown
- Lead developer
- Lesaffre
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus subtilis CU1 is a probiotic strain of Bacillus subtilis, classified as Bacillus subtilis subsp. spizizenii, developed for use as an ingredient in food and dietary supplements. It has been clinically studied in elderly and adult populations for its ability to stimulate systemic and mucosal immune responses. Mechanisms include priming the innate immune system, increasing secretion of immunoglobulin A (SIgA) in stool and saliva, and upregulating activation markers (e.g., CD69) on monocytes. It also enhances phagocytosis and increases production of pro-inflammatory cytokines upon challenge, while reducing basal levels of inflammatory cytokines in elderly subjects. It produces antimicrobial substances, such as amicoumacins, and may antagonize gastrointestinal pathogens, modulate gut microbiota, and enhance epithelial barrier function. Clinical studies indicate safety and good tolerability in humans, with no significant antibiotic resistance, hemolytic activity, or toxigenic effects[1][2][3][5].
- Brand names
- LifeinU Bacillus subtilis CU1
- Other names
- Bacillus subtilis CU1BSCU1BSCU-1BSCU 1CNCM I-2745
02
Targets
sIgA (Secretory immunoglobulin A)
Beyond the preview
Go deeper on Bacillus subtilis CU1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacillus subtilis CU1.